Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

Ultragenyx Pharmaceutical is well-positioned for growth in the coming years, with strong indications of profitability by FY27 and significant expense reductions planned for that period. The company's FY26 revenue guidance is on track for 10% year-over-year growth, and the potential monetization of Priority Review Vouchers, as well as upcoming catalysts such as FDA decisions on potential approvals for gene therapies, add to the positive outlook for Ultragenyx. Furthermore, the company's significant expense reduction plan reflects investor concerns and could potentially lead to a higher valuation for its base commercial business.

Ultragenyx Pharmaceutical is facing a negative outlook due to its recent failure of its GTX-102 drug in the Aspire trial for Angelman syndrome, one of the largest trials in the space. With this failure, the company has removed GTX-102 from its estimates and will have to adjust its spending trajectory, potentially leading to significant expense reductions. The next clinical catalysts for the company are its gene therapies, but there are also key risks such as lower-than-expected revenues and competition in the rare disease space.